Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. More Details
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Elekta's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EKTA B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: EKTA B's weekly volatility (5%) has been stable over the past year.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: EKTA B underperformed the Swedish Medical Equipment industry which returned 14.9% over the past year.
Return vs Market: EKTA B underperformed the Swedish Market which returned 18.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Elekta's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHere’s What’s Happening With Returns At Elekta (STO:EKTA B)
3 weeks ago | Simply Wall StA Look At The Intrinsic Value Of Elekta AB (publ) (STO:EKTA B)
1 month ago | Simply Wall StIs Elekta AB (publ) (STO:EKTA B) A Good Fit For Your Dividend Portfolio?
Is Elekta undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EKTA B (SEK107) is trading above our estimate of fair value (SEK86.52)
Significantly Below Fair Value: EKTA B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EKTA B is poor value based on its PE Ratio (35.5x) compared to the SE Medical Equipment industry average (32.3x).
PE vs Market: EKTA B is poor value based on its PE Ratio (35.5x) compared to the Swedish market (22.6x).
Price to Earnings Growth Ratio
PEG Ratio: EKTA B is poor value based on its PEG Ratio (2.6x)
Price to Book Ratio
PB vs Industry: EKTA B is overvalued based on its PB Ratio (5.2x) compared to the SE Medical Equipment industry average (4.3x).
How is Elekta forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EKTA B's forecast earnings growth (13.9% per year) is above the savings rate (0.5%).
Earnings vs Market: EKTA B's earnings (13.9% per year) are forecast to grow faster than the Swedish market (11.4% per year).
High Growth Earnings: EKTA B's earnings are forecast to grow, but not significantly.
Revenue vs Market: EKTA B's revenue (6.5% per year) is forecast to grow faster than the Swedish market (3.3% per year).
High Growth Revenue: EKTA B's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EKTA B's Return on Equity is forecast to be low in 3 years time (17.6%).
How has Elekta performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EKTA B has high quality earnings.
Growing Profit Margin: EKTA B's current net profit margins (8%) are lower than last year (8.4%).
Past Earnings Growth Analysis
Earnings Trend: EKTA B's earnings have grown significantly by 30.9% per year over the past 5 years.
Accelerating Growth: EKTA B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EKTA B had negative earnings growth (-2.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (49.3%).
Return on Equity
High ROE: EKTA B's Return on Equity (14.7%) is considered low.
How is Elekta's financial position?
Financial Position Analysis
Short Term Liabilities: EKTA B's short term assets (SEK14.6B) exceed its short term liabilities (SEK10.2B).
Long Term Liabilities: EKTA B's short term assets (SEK14.6B) exceed its long term liabilities (SEK8.7B).
Debt to Equity History and Analysis
Debt Level: EKTA B's debt to equity ratio (100.2%) is considered high.
Reducing Debt: EKTA B's debt to equity ratio has increased from 89.6% to 100.2% over the past 5 years.
Debt Coverage: EKTA B's debt is well covered by operating cash flow (23.6%).
Interest Coverage: EKTA B's interest payments on its debt are well covered by EBIT (12.6x coverage).
What is Elekta current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EKTA B's dividend (0.84%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.18%).
High Dividend: EKTA B's dividend (0.84%) is low compared to the top 25% of dividend payers in the Swedish market (3.74%).
Stability and Growth of Payments
Stable Dividend: EKTA B's dividend payments have been volatile in the past 10 years.
Growing Dividend: EKTA B's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.8%), EKTA B's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: EKTA B's dividends in 3 years are forecast to be well covered by earnings (43.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gustaf Salford (43 yo)
Mr. Gustaf Salford serves as Acting President and Chief Executive Officer at Elekta AB (publ) since June 2, 2020. He served as Chief Financial Officer and Executive Vice President of Elekta AB (publ) since...
|Founder & Chairman||7.17yrs||kr1.40m||2.11% |
|Acting President & CEO||0.42yr||no data||0.0019% |
|Group Treasurer & Acting CFO||0.42yr||no data||0.0010% |
|Head of Investor Relations||1.5yrs||no data||no data|
|General Counsel||4yrs||no data||0.000050% |
|Head of Corporate Communications & Public Affairs||no data||no data||no data|
|Executive VP of APAC||3.25yrs||no data||no data|
|Executive Vice President of Human Resources||3.83yrs||no data||0.00031% |
|Head of External Relations||5.33yrs||no data||no data|
|President of Brachy Solutions||8.42yrs||no data||0.00046% |
|President of Linac solutions||6.25yrs||no data||0.0042% |
|Executive VP & Head of Region China||no data||no data||no data|
Experienced Management: EKTA B's management team is considered experienced (3.8 years average tenure).
|Founder & Chairman||7.17yrs||kr1.40m||2.11% |
|Independent Director||10.83yrs||kr700.00k||0.0075% |
|Independent Director||9.83yrs||kr630.00k||0.0046% |
|Independent Director||5.83yrs||kr700.00k||0.0052% |
|Independent Director||15.83yrs||kr790.00k||0.0016% |
|Independent Director||2.25yrs||kr630.00k||0.00029% |
Experienced Board: EKTA B's board of directors are considered experienced (7.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EKTA B insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Elekta AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Elekta AB (publ)
- Ticker: EKTA B
- Exchange: OM
- Founded: 1972
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr40.883b
- Shares outstanding: 382.08m
- Website: https://www.elekta.com
Number of Employees
- Elekta AB (publ)
- Kungstensgatan 18
- Box 7593
- Stockholm County
- 103 93
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EKTA.F||OTCPK (Pink Sheets LLC)||Yes||Series B Registered Shares||US||USD||Mar 1994|
|EKTA B||OM (OMX Nordic Exchange Stockholm)||Yes||Series B Registered Shares||SE||SEK||Mar 1994|
|EJXB||DB (Deutsche Boerse AG)||Yes||Series B Registered Shares||DE||EUR||Mar 1994|
|0O5H||LSE (London Stock Exchange)||Yes||Series B Registered Shares||GB||SEK||Mar 1994|
|EKTABS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Series B Registered Shares||GB||SEK||Mar 1994|
|EKTA.Y||OTCPK (Pink Sheets LLC)||UNSPONSOD ADR||US||USD||Dec 2008|
Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery ac...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/23 22:02|
|End of Day Share Price||2020/11/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.